Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Drug

Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China

Fineline Cube Apr 12, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to...

Company Drug

Junshi Biosciences’ Senaparib Meets Primary Endpoint in Phase III Ovarian Cancer Study

Fineline Cube Apr 12, 2023

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has declared that the Phase III FLAMES study...

Company

Porton Pharma Solutions Expands with Biomacromolecules R&D and Manufacturing Center in Shanghai

Fineline Cube Apr 12, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions has initiated the construction of...

Company Deals

Blueray Med Secures Tens of Millions in Series A+ Financing for Advanced Laser Medicine Devices

Fineline Cube Apr 12, 2023

Blueray Med, a leading high-end laser medicine device manufacturer based in Xi’an, has reportedly secured...

Company Deals

Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC

Fineline Cube Apr 12, 2023

Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...

Company

Legend Biotech Appoints Dr. Mythili Koneru as Chief Medical Officer to Lead Clinical Development

Fineline Cube Apr 12, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the appointment of Dr. Mythili Koneru as...

Company Drug

Luye Pharma’s Bevacizumab Biosimilar Accepted for Review in Brazil by ANVISA

Fineline Cube Apr 12, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that the market approval filing for its...

Policy / Regulatory

Round 8 VBP Tender Results: RMB 3.775 Billion Awarded Across 152 Manufacturers

Fineline Cube Apr 12, 2023

The official results of Round 8 of China’s national Volume-Based Procurement (VBP) tender program have...

Company Drug

Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE

Fineline Cube Apr 12, 2023

The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...

Company Drug

Bristol-Myers Squibb Launches Zeposia in China for Multiple Sclerosis Treatment

Fineline Cube Apr 11, 2023

Global pharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced the market launch in China...

Policy / Regulatory

Hubei Implements Inter-Provincial VBP Tender Results for Pacemakers

Fineline Cube Apr 11, 2023

The Hubei provincial Drug and Instrument Procurement Platform has issued a notice regarding the implementation...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns FDA Approval for Small-Cell Lung Cancer Trial

Fineline Cube Apr 11, 2023

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from...

Company Drug

JW Therapeutics’ Carteyva Receives NMPA Approval for Moderate-to-Severe SLE Clinical Trial

Fineline Cube Apr 11, 2023

China-based JW Therapeutics (HKG: 2126) has announced receiving tacit clinical trial approval from the National...

Company Deals Digital

Hua Medicine Partners with 111 Inc. for Dorzagliatin Sales and Distribution in China

Fineline Cube Apr 11, 2023

China-based Hua Medicine (HKG: 2552) has announced a sales and distribution agreement with online pharma...

Company

CStone Pharmaceuticals Reduces Ayvakit Price to Boost Accessibility in China

Fineline Cube Apr 11, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced a lower recommended price for its precision medicine...

Company Deals

Hangzhou Baikai Biomedical and Leads Biolabs Partner to Develop Innovative ADCs

Fineline Cube Apr 11, 2023

China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed...

Hospital Policy / Regulatory

NHC Report: Performance Assessment of National Class 2 Public Hospitals in 2021

Fineline Cube Apr 11, 2023

The National Health Commission (NHC) has released the “Report on the National Monitoring and Analysis...

Company Deals

Cuban-Chinese Biotechnology Center Showcases Drug and Vaccine Progress to Cuban Delegation

Fineline Cube Apr 11, 2023

Researchers from Cuba and China at the Yongzhou joint biotechnology innovation center in China’s Hunan...

Medical Device Policy / Regulatory

Hebei Leads Sanming Alliance in Launching 8th VBP for 19 Medical Consumables

Fineline Cube Apr 11, 2023

The Hebei medical drug and device centralized procurement center has announced the start of the...

Company Drug

Takeda Pharma’s Iclusig Poised for Priority Review by CDE for Leukemia Treatments

Fineline Cube Apr 11, 2023

The Center for Drug Evaluation (CDE) website has indicated that Takeda Pharma’s (TYO: 4502) Iclusig...

Posts pagination

1 … 565 566 567 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.